We are live on
!
Find out more
CAM
Cormorant Asset Management Portfolio holdings
AUM
$1.99B
1-Year Est. Return
737.95%
This Fund
S&P 500
This Quarter
Est. Return
+44.2%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$2.62B
AUM Growth
+$469M
(+22%)
Cap. Flow
-$157M
Cap. Flow
% of AUM
-5.99%
Top 10 Holdings %
Top 10 Hldgs %
40.11%
Holding
87
New
14
Increased
8
Reduced
51
Closed
6
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
FMTX
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
|
+$147M |
| 2 |
RNAM
Avidity Biosciences
RNAM
|
+$72.5M |
| 3 |
Arcturus Therapeutics
ARCT
|
+$18.5M |
| 4 |
Pliant Therapeutics
PLRX
|
+$16.2M |
| 5 |
uniQure
QURE
|
+$11.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CNST
Constellation Pharmaceuticals, Inc.
CNST
|
+$64.1M |
| 2 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$33.9M |
| 3 |
PRNB
Principia Biopharma Inc. Common Stock
PRNB
|
+$31.5M |
| 4 |
XLRN
Acceleron Pharma
XLRN
|
+$21.7M |
| 5 |
IMVTU
Immunovant, Inc. Units
IMVTU
|
+$19.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 81.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ALLK
51
DELISTED
Allakos
ALLK
| $14.2M | 0.54% |
197,515
-2,485
| -1% | -$166K |
|
52
Inspire Medical Systems
INSP
$1.74B
| $12.9M | 0.49% |
147,982
-2,018
| -1% | -$155K |
|
53
Insmed
INSM
$28.6B
| $12.4M | 0.47% |
450,000
+87,727
| +24% | +$2.08M |
|
54
BioNTech
BNTX
$23.5B
| $11.7M | 0.45% |
+175,000
| New | +$8.74M |
|
55
Kura Oncology
KURA
$850M
| $11.4M | 0.44% |
700,000
-100,000
| -13% | -$1.44M |
|
|
RPTX
56
DELISTED
Repare Therapeutics
RPTX
| $10.9M | 0.42% |
+352,795
| New | +$11.3M |
|
|
HARP
57
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
| $10.7M | 0.41% |
64,526
-473
| -0.7% | -$73.8K |
|
|
AKUS
58
DELISTED
Akouos Inc
AKUS
| $10.7M | 0.41% |
+499,990
| New | +$11.1M |
|
|
MRUS
59
DELISTED
Merus
MRUS
| $9.65M | 0.37% |
600,000
| – | – |
|
|
KDMN
60
DELISTED
Kadmon Holdings, Inc.
KDMN
| $9.22M | 0.35% |
+1,800,000
| New | +$8.07M |
|
61
Q32 Bio
QTTB
$464M
| $8.36M | 0.32% |
30,556
-2,777
| -8% | -$740K |
|
|
AUTL
62
Autolus Therapeutics
AUTL
$562M
| $7.69M | 0.29% |
479,988
| – | – |
|
|
AVEO
63
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
| $6.95M | 0.27% |
+1,350,000
| New | +$8.52M |
|
|
BCEL
64
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
| $6.84M | 0.26% |
321,322
-4,817
| -1% | -$85.1K |
|
|
BNR
65
Burning Rock Biotech
BNR
$92.9M
| $6.75M | 0.26% |
+25,000
| New | +$6.85M |
|
|
KZR
66
DELISTED
Kezar Life Sciences
KZR
| $6.73M | 0.26% |
+130,000
| New | +$6.56M |
|
|
EIGR
67
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $6.72M | 0.26% |
23,333
-3,838
| -14% | -$1.13M |
|
|
GTH
68
DELISTED
Genetron Holdings Limited ADS
GTH
| $6.04M | 0.23% |
+166,667
| New | +$6.76M |
|
|
TECX
69
Tectonic Therapeutic
TECX
$585M
| $5.54M | 0.21% |
26,465
| – | – |
|
|
ARNA
70
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $4.72M | 0.18% |
75,000
-25,000
| -25% | -$1.38M |
|
|
ARYBU
71
DELISTED
ARYA Sciences Acquisition Corp II Unit
ARYBU
| $4.64M | 0.18% |
+400,000
| New | +$4.4M |
|
72
Gossamer Bio
GOSS
$87M
| $4.54M | 0.17% |
349,325
+150,943
| +76% | +$1.9M |
|
|
AMRN
73
Amarin Corp
AMRN
$303M
| $4.15M | 0.16% |
30,000
-15,000
| -33% | -$2.06M |
|
74
Nektar Therapeutics
NKTR
$2.58B
| $2.9M | 0.11% |
8,333
-1,667
| -17% | -$520K |
|
75
Precision BioSciences
DTIL
$207M
| $2.89M | 0.11% |
11,551
| – | – |
|
Similar funds
SC
RMCM
RCM
LGM
MYAM
C
TCM
BGM
Cormorant Asset Management's Q2 2020 Portfolio in Review
As of Q2 2020, Cormorant Asset Management held 87 positions worth $2.62B, up 22% from $2.15B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Cormorant Asset Management withdrew a net $157M in Q2 2020, closing 6 positions and reducing 51 holdings. Its most notable exit was Constellation Pharmaceuticals, Inc., an estimated $64.1M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 76% a quarter earlier.
Against the trend, Cormorant Asset Management opened a new position in Forma Therapeutics Holdings, Inc. Common Stock worth $153M.
- Cormorant Asset Management's largest Q2 2020 buy was Forma Therapeutics Holdings, Inc. Common Stock: 3,379,373 shares worth $153M.
- Cormorant Asset Management added most to Arcturus Therapeutics in Q2 2020, an estimated $18.5M increase.
- Cormorant Asset Management's biggest Q2 2020 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $33.9M.
- Cormorant Asset Management fully exited Constellation Pharmaceuticals, Inc. in Q2 2020, selling an estimated $64.1M.
- Cormorant Asset Management's ten largest holdings make up 40% of its $2.62B portfolio in Q2 2020.
- Cormorant Asset Management opened 14 new positions and closed 6 in Q2 2020.
- Cormorant Asset Management's portfolio value rose 22% quarter-over-quarter to $2.62B.
Based on Cormorant Asset Management's 13F filing for Q2 2020, filed 14 Aug 2020.